New York, January 24, 2026, 16:07 EST — Market closed
- Thermo Fisher Scientific shares dropped 2.1% on Friday, ending a three-day rally.
- The stock slipped back after hitting a fresh 52-week high just yesterday.
- With this week behind them, investors are shifting focus to next week’s earnings reports and key macro data for guidance on the market’s next move.
Shares of Thermo Fisher Scientific Inc dropped 2.11% on Friday, closing at $625.98 after hitting a 52-week high just the day before. The broader U.S. market ended the session mixed. Volume exceeded recent averages, indicating some investors were cashing out ahead of a busy week packed with catalysts.
Thermo Fisher’s role as a bellwether for life-sciences tools and lab services gives this moment added weight — this sector often shifts on subtle moves in biotech funding and pharma spending. The stock hit a fresh high, but now it enters earnings season with little margin for error or guarded guidance.
Thermo Fisher plans to report its fourth-quarter and full-year 2025 results before markets open on Thursday, Jan. 29. A conference call will follow at 8:30 a.m. ET. Investors are keen to hear management’s views on pharma services demand and the speed of lab spending, beyond just the headline earnings.
Macro factors might steer the tone as well. The Federal Reserve’s rate-setting panel convenes Jan. 27–28, with a press conference slated for Jan. 28 — right in the middle of the week, a timing that frequently triggers quick, significant swings in high-value, long-duration stocks.
Danaher, a key competitor to Thermo Fisher, will webcast its Q4 earnings call on Wednesday, Jan. 28 at 8:00 a.m. ET. Traders often treat this report as an early indicator of demand trends for instruments, diagnostics, and lab equipment.
Late in the week, a separate filing popped up. A Form 25 — which signals the removal of a security from an exchange listing and registration — revealed Thermo Fisher’s 1.400% senior notes due 2026 are being delisted from the New York Stock Exchange. This move affects the company’s debt securities only, not its common stock.
Earlier this month, CEO Marc Casper revealed that Thermo Fisher had landed contracts via its pharma services division to assist clients in moving some drug production back to the U.S., a shift he attributed to tariff discussions and policy changes. Evercore ISI analyst Vijay Kumar called the company’s outlook “positive” and “cautiously encouraging” as it looks toward 2026. Reuters
The risk is clear-cut. Should Thermo Fisher’s guidance suggest customers are delaying orders even further, or if margins tighten, the stock might lose more of its recent gains — especially if the broader market jitters ahead of the Fed meeting.
Thermo Fisher kicks off Monday with investors paying less attention to Friday’s drop and more eyeing two key dates: Danaher’s earnings on Jan. 28, followed by Thermo Fisher’s own report and guidance a day later, on Jan. 29.
